Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure

Back to Agenda

Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact

Session Chair(s)

Martine Dehlinger-Kremer, PhD

VP Scientific Affairs, Pediatric SME, ICON Plc & President, EUCROF

Icon Plc, Germany

Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact

Speaker(s)

EMA Regulatory Science Strategy 2025 - How Will It Impact Paediatric Development?

Ralph Bax, MD, PhD

European Medicines Agency, Netherlands

Head of the Paediatric Medicines Office

Panel Discussion

Dimitrios Athanasiou, MBA

WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS, Greece

Patient Advocate

Panel Discussion

Geneviève Le Visage, PharmD, MSc

Novartis Pharma AG, Switzerland

Head EU RA Policy and Liaison

Panel Discussion

Siri Wang

Norwegian Medical Products Agency, Norway

Scientific Director; PDCO delegate

Have an account?

Better Medicines for Children, A DIA/EFGCP Conference

Session 1: Innovative Approaches to Paediatric Drug Development – State of Play and Possible Impact

Session Chair(s)

Martine Dehlinger-Kremer, PhD

Speaker(s)

EMA Regulatory Science Strategy 2025 - How Will It Impact Paediatric Development?

Panel Discussion

Panel Discussion

Panel Discussion

Be informed and stay engaged.